Mitochondrial inner membrane and associated bioenergetic machinery (MIM/OXPHOS)

The mitochondrial inner membrane (MIM) and its associated bioenergetic machinery, primarily the oxidative phosphorylation (OXPHOS) system, serve as the primary site for cellular ATP production via the electron transport chain (ETC) and ATP synthase (Complex V) (StatPearls, 2023; UniProt, 2024). This complex system comprises five multi-subunit protein complexes (Complexes I-V) and two mobile electron carriers, ubiquinone and cytochrome c, embedded within a protein-rich lipid bilayer containing the unique phospholipid cardiolipin (Wikipedia, 2024; NIH, 2023). Beyond bioenergetics, the MIM machinery is integral to regulating the mitochondrial permeability transition pore (mPTP), reactive oxygen species (ROS) generation, and the initiation of the intrinsic apoptotic pathway (PubMed, 2022). Dysfunction in these components is a hallmark of various conditions, including primary mitochondrial diseases (e.g., Leigh syndrome), neurodegenerative disorders like Parkinson's disease, and metabolic diseases such as type 2 diabetes (Nature Reviews Drug Discovery, 2021). Therapeutic strategies targeting this machinery include the use of ETC inhibitors (e.g., metformin for Complex I), uncoupling agents to increase metabolic rate, and membrane stabilizers like elamipretide that target cardiolipin to restore structural integrity (PubChem, 2024; Stealth BioTherapeutics, 2023). However, because mitochondrial function is essential for nearly all eukaryotic cells, pharmacological modulation of the MIM machinery often presents significant safety challenges, including the risk of lactic acidosis and systemic toxicity (FDA, 2023).

Other names

Mitochondrial inner membraneOxidative phosphorylation systemOXPHOSElectron transport chainETC

Inhibition of Complex I, Inhibition of Complex IV, Uncoupling of oxidative phosphorylation, Inhibition of ATP synthase, Stabilization of cardiolipin-protein complexes